Incidence of hand-foot syndrome with protein kinase inhibitors in advanced hepatocellular carcinoma patients who received atezolizumab-bevacizumab combination.

MLA

Perrier, Marine, et al. “Incidence of Hand-Foot Syndrome with Protein Kinase Inhibitors in Advanced Hepatocellular Carcinoma Patients Who Received Atezolizumab-Bevacizumab Combination.” Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners, vol. 30, no. 8, Dec. 2024, pp. 1432–36. EBSCOhost, https://doi.org/10.1177/10781552241269738.

APA

Perrier, M., Zuccaro, E., Carlier, C., Brugel, M., Slimano, F., & Bouché, O. (2024). Incidence of hand-foot syndrome with protein kinase inhibitors in advanced hepatocellular carcinoma patients who received atezolizumab-bevacizumab combination. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners, 30(8), 1432–1436. https://doi.org/10.1177/10781552241269738

Chicago

Perrier, Marine, Emma Zuccaro, Claire Carlier, Mathias Brugel, Florian Slimano, and Olivier Bouché. 2024. “Incidence of Hand-Foot Syndrome with Protein Kinase Inhibitors in Advanced Hepatocellular Carcinoma Patients Who Received Atezolizumab-Bevacizumab Combination.” Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners 30 (8): 1432–36. doi:10.1177/10781552241269738.